Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIR T INCAIRT · Entity 6862 | CFO | October 16, 2024 | August 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIR T INC
Report date October 16, 2024 · Filed August 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $33.98 · Expires 2041-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-10-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount outstanding as of 10/16/2024 was 1,750. For further details, see the Company's proxy statement filed July 3, 2025. |
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $36.78 · Expires 2041-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-10-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount outstanding as of 10/16/2024 was 1,750. For further details, see the Company's proxy statement filed July 3, 2025. |
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $39.76 · Expires 2041-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-10-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount outstanding as of 10/16/2024 was 1,750. For further details, see the Company's proxy statement filed July 3, 2025. |
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $42.93 · Expires 2041-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-10-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount outstanding as of 10/16/2024 was 1,750. For further details, see the Company's proxy statement filed July 3, 2025. |
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $46.29 · Expires 2041-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-10-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount outstanding as of 10/16/2024 was 1,750. For further details, see the Company's proxy statement filed July 3, 2025. |
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $49.85 · Expires 2041-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-10-16 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F1: Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount outstanding as of 10/16/2024 was 1,750. For further details, see the Company's proxy statement filed July 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount outstanding as of 10/16/2024 was 1,750. For further details, see the Company's proxy statement filed July 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2025 Filed Aug 14, 2025 19:46 UTC | AIR T INC AIRT · Entity 6862 | GrantStock options · Derivative | 2,000 | $0.00 Strike: $50.00 | $0.00 |
DisclosureSEC source: 0000353184-25-000089 · wk-form4_1755200779.xml · derivative · entry 2 Kennedy Tracy · CIK 0002059629 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2045-08-06 F1 · balance_after: Cumulative amount does not include presently unexerciseable options granted in December 2020. Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount currently outstanding is 15,000. For further details, see the Company's proxy statement filed July 3, 2025. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 19:46 UTC | AIR T INC AIRT · Entity 6862 | GrantStock options · Derivative | 2,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0000353184-25-000089 · wk-form4_1755200779.xml · derivative · entry 1 Kennedy Tracy · CIK 0002059629 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2045-08-06 F1 · balance_after: Cumulative amount does not include presently unexerciseable options granted in December 2020. Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount currently outstanding is 15,000. For further details, see the Company's proxy statement filed July 3, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.